article thumbnail

6 challenges healthtech can help us tackle – Pt.2

Digital Health Global

Drug development The traditional drug discovery process is characterized by its protracted timeline, high costs, and significant attrition rates among drug candidates. There are three main advantages to the use of AI in drug development: width of research, speed of execution, low costs. DiMasi, H.G.

article thumbnail

Debiopharm Innovation Fund Launches New Seed Funding Activity to Accelerate Digital Transformation of Cancer Care and Pharma R&D

Digital Health Global

Investments will focus on the next generation of pharma R&D to accelerate drug development, on new technology solutions enabling a more patient-centric approach in clinical trials, and on digital platforms uncovering new insights from clinical data for more personalized care pathways.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Virtual Care – negotiating barriers to adoption offers glimpses of an exciting future

Lloyd Price

Transforming healthcare A report from the London School of Economics, The Role of Virtual Health Care and the Pharmaceutical Sector in Improving Population Health , published in 2021, forecast that the pharmaceutical industry would be a core player in all aspects from population health management to preventive and therapeutic care.

article thumbnail

Where are HealthTech's soft landing M&A deals in today's market?

Lloyd Price

Traditional healthcare players: Hospitals, insurers, and pharmaceutical companies are increasingly acquiring healthtech startups to improve efficiency, patient engagement, and data-driven decision making. Develop personalized medicine approaches. Soft landing" deals could provide a valuable pathway for them.

article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. She was the patient keynote speaker at DPHARM 2021 and is a HIMSS Digital Health Influencer. How do we get the patient to actually be the one improving patient experience?

BioTech 107
article thumbnail

Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to Acquire the Company’s Digital Pathology Business

Healthcare IT Today

Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development. “A

article thumbnail

How to Leverage DTx with Your Digital Health Strategy | Part 1 of 2

Xealth

Its interest in DTx exists specifically in remote patient monitoring because of the potential to provide valuable insights throughout drug development life cycles. Big Pharma is driving much of the speculation. Several big players have joined the DTA, which doubled in membership in 2022.